|
|
||||||||
1From the Department of Ophthalmology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel; and the 2Michaelson Institute for vision rehabilitation, Hadassah-Hebrew University Medical Center, Jerusalem, Israel.
| Abstract |
|---|
|
|
|---|
METHODS. Ophthalmic evaluation included a full clinical examination, perimetry, color vision testing, and electroretinography. Genomic DNA was screened for ABCA4 mutations with the use of microarray analysis and direct sequencing. RNA analysis was performed with RT-PCR and sequencing.
RESULTS. The authors recruited 15 patients with a unique retinal disease who are members of six highly consanguineous Arab-Muslim families from a single village. During early stages of disease, funduscopic and angiographic findings as well as retinal function resemble those of Stargardt disease. However, later in life, severe, widespread cone-rod degeneration ensues. Marked progressive involvement of the retinal periphery distinguishes this phenotype from classic Stargardt disease. Genetic analysis of ABCA4 revealed two novel deletions, p.Cys1150del and c.4254-15del23. One patient, who was a compound heterozygote, manifested typical Stargardt disease. The remaining 14 patients were homozygote for the c.4254- 15del23 intronic deletion and had the progressive form of disease. We identified an identical ABCA4 haplotype in all alleles carrying this mutation, indicating a founder mutation. Detailed RT-PCR analysis in normal retina and lymphoblastoid cells revealed expression of the full-length ABCA4 transcript and three novel transcripts produced by alternative splicing. The full-length ABCA4 transcript, however, could not be detected in lymphoblastoid cells of affected homozygote patients.
CONCLUSIONS. These results expand the genotype-phenotype correlation of ABCA4, showing that homozygosity for the novel c.4254-15del23 splicing mutation is associated with a severe progressive form of disease.
Mutations in ABCA4 cause a variety of retinal diseases.3 4 5 ABCA4 is the only gene known to cause autosomal recessive (AR) Stargardt disease (detection rate, 58%–78%).6 7 Patients with Stargardt disease experience central visual loss in the first two decades of life, often with an initially normal fundus appearance. Later on, Stargardt disease is associated with macular atrophy and yellowish deep retinal flecks, while peripheral vision is largely preserved. Three different subtypes of Stargardt disease have been described based on electroretinal findings,8 9 with group 3 the most severe phenotype in which peripheral retinal involvement occurs in addition to maculopathy. ABCA4 mutations were also found in a few patients with AR retinitis pigmentosa, a progressive retinal degeneration that initially affects the rod photoreceptors but that ultimately also leads to gradual loss of cones. Mutations in ABCA4 have also been identified in 30% to 50% of patients with AR cone-rod degeneration (CRD),5 10 in which cones are initially affected and rod degeneration ensues. The involvement of ABCA4 in age-related macular degeneration is still controversial, but accumulating data point to involvement in a small percentage of cases.11
We describe here a detailed clinical and genetic analysis of patients from six families residing in the same village who manifest a unique retinal degeneration caused by novel ABCA4 mutations. In addition, we describe the existence of novel ABCA4 transcripts, produced by alternative splicing, in the normal retina.
| Patients and Methods |
|---|
|
|
|---|
Clinical Evaluation
Full ophthalmologic examination, including assessment of visual acuity (VA), ocular motility, pupillary reaction, biomicroscopic slit-lamp, and dilated fundus examination, was performed in all patients. Subsequently, kinetic perimetry (Goldman visual fields, targets V4e and III4e), color vision testings, full-field electroretinography (ERG), and electrooculography (EOG) were performed.13 Full-field ERGs were recorded using corneal electrodes and a computerized system (UTAS 3000; LKC, Gaithersburg, MD). In the dark-adapted state, a rod response to a dim blue flash and a mixed cone-rod response to a white flash were acquired. Cone responses to 30-Hz flashes of white light were acquired under a background light of 21 cd/m2. All ERG responses were filtered at 0.3 to 500 Hz, and signal averaging was used. EOG was performed according to the International Society for Clinical Electrophysiology of Vision (ISCEV) standard using bilateral skin electrodes on both canthi, and the Arden ratio (light peak to dark trough) was derived.14
ABCA4 Haplotype Analysis
DNA amplification was performed by 35 cycles consisting of denaturation at 94°C, annealing at 54°C, and extension at 72°C for 30 seconds each. In addition, an initial denaturation and final extension steps of 5 minutes each were performed. Haplotype analysis included four microsatellite markers (D1S435, D1S188, D1S2719, D1S497) flanking ABCA4 and two single nucleotide polymorphisms (SNPs; rs472908 and rs560426 with 5 U NEB enzyme Tsp509I at 65°C and Hpy188III at 37°C, respectively) located within ABCA4. Restriction products were separated by electrophoresis in 3% agarose gel for 50 minutes.
Mutation Analysis
The single-strand conformation polymorphism and direct sequencing techniques were used to screen all 50 coding exons of ABCA4 (Refseq NM_000350.2). Screening for all known ABCA4 sequence changes was performed at Asper Biotech using the ABCA4 genotyping microarray (http://www.asperophthalmics.com/ABCRgenetest.htm).6
Reverse Transcription and Nested PCR Analysis
We used a previously described protocol15 to study ABCA4 splicing. Total RNA was isolated from Epstein-Barr virus-transformed lymphoblastoid cells (RNeasy; Qiagen, Valencia, CA). RT-PCR was performed (Reverse-iT; Abgene, Epsom, UK) with random decamers, and cDNA amplification was performed with primers 737f (5'-aacgtcaacccccgacac-3') and 738r (5'-tcctgtccgtcaggtcttg-3'). This was followed by a nested-PCR reaction with primers 351f (5'-ctacctttgtgtttttggctctg-3') and 257r (5'-actctggcagcatggtgag-3'). PCR products were gel purified and sequenced. We used the Splice-Site Prediction by Neural Network (http://www.fruitfly.org/seq_tools/splice.html) for prediction of splice-site sequences.
| Results |
|---|
|
|
|---|
|
A representative example of the early stage of disease is patient MOL0033 II-4. At 14 years of age, her VA was 6/60, and yellow flecks and macular atrophy were evident (Fig. 2A) . Fluorescein angiography showed hyperfluorescence of the flecks and staining of atrophy in the macular region with a dark choroid effect in the background (Fig. 2B) , characteristic of Stargardt disease. In older patients, however, large areas of atrophy and grayish discoloration of the retina were evident, with pigment migration and large pigment clumps in the posterior pole, midperiphery, and along the vessels (Figs. 2D 2E 2F) . These findings suggest widespread retinal degeneration, beyond that usually associated with typical Stargardt disease. The progressive nature of the disease can be appreciated in the serial images of patient MOL0006 II-7 (Figs. 2G 2H 2I) . At the age of 8, his VA was 6/30, and macular changes were slight (Fig. 2G) . At the age of 12, his VA dropped to 6/60, and macular changes were more pronounced yet still compatible with typical Stargardt (Fig. 2H) . However, at age 18 (VA 6/60), widespread retinal involvement was evident with atrophy and pigment clumps (Figs. 2I 2J 2K 2L) . Interestingly, autofluorescence imaging showed a relatively preserved parapapillary ring (Fig. 2K) , as previously noted in patients with ABCA4 mutations.16
|
|
|
The only exception to this pattern of progression was patient MOL0006 I-2. At the age of 40, her fundus findings remained localized to the macular area, which had a typical Stargardt-like appearance (Fig. 2C) . Full-field ERG function was maintained within normal limits, and EOG findings were at the lower limit of normal (Fig. 4 , squares). This exception can be explained by the molecular genetic findings detailed below.
Haplotype and Mutation Analysis
Given the retinal phenotype described and the inheritance pattern of the six families, we considered ABCA4 the major candidate gene causative of the disease. Therefore, we performed haplotype analysis of families MOL0006 and MOL0033 using DNA markers located within and flanking the ABCA4 gene (Fig. 1B) . In family MOL0006, two different haplotypes, 1 and 3, cosegregated with the disease under the assumption of AR inheritance. Patient MOL0006 I-2 (diagnosed with typical Stargardt) carried both haplotypes, and her unaffected husband carried haplotypes 1 and 2; the latter did not cosegregate with the disease. All affected children, diagnosed with progressive, severe Stargardt-like disease, were homozygote for haplotype 1. In family MOL0033, two haplotypes, 4 and 6, shared an identical portion within ABCA4 and cosegregated with the disease. Moreover, haplotype 1, cosegregating in family MOL0006, shared the same ABCA4 portion with haplotypes 4 and 6.
Based on these data, we assumed that two different ABCA4 mutations were responsible for the two retinal phenotypes, one of which is shared by haplotypes 1, 4, and 6. To identify these mutations, we screened the DNA of two affected patients for all known ABCA4 sequence variants by using the Asper biotech ABCA4 mutation detection microarray.6 The screen revealed seven sequence changes (c.1269C>T [p.His423His], c.1356+5delG, c.4773+48C>T, c.6069C>T [p.Ile2023Ile], c.6249C>T [p.Ile2083Ile], c.6285T>C [p.Asp2095Asp], and c.6764G>T [p.Ser2255Ile]) that had been previously interpreted as nonpathogenic changes. We subsequently performed mutation screening of the whole ABCA4 open-reading-frame and identified two previously reported nonpathogenic changes (c.6282+7G>A and c.302+26A>G) and a novel in-frame deletion (c.3449_3451delGCT [p.Cys1150del]) in exon 23, found heterozygously in patient MOL0006 I-2 (Fig. 5A) . The deleted amino acid (Cys1150) is highly conserved, resides within a conserved ABCA4 region (Fig. 5A , bottom), and is located at the 3'-end of the ABC transporter nucleotide-binding domain. We could not identify this mutation in 190 chromosomes from healthy Arab-Muslim control subjects, nor could we find it in 30 unrelated Arab-Muslim patients with Stargardt disease or CRD. We considered it a pathogenic ABCA4 mutation. We could not identify a second ABCA4 mutation in our mutation analysis of the remaining exons, but we were consistently unable to amplify exon 29 by PCR using the DNA of patients with a diagnosis of progressive Stargardt-like disease. We performed a long-range PCR reaction and amplified the region encompassing exon 29. Sequencing analysis of this fragment revealed an intronic deletion of 23 nucleotides overlapping with the forward primer of exon 29. The deletion (c.4254- 15del23 [IVS28-15del23bp]) was located 15 bp upstream of exon 29 (Fig. 5B) , and computer splice-site prediction analysis revealed a high score (0.83 of 1.00) for the wild-type acceptor site; the score for the mutant site was much lower (0.44 of 1.00). The mutation was shared by patients from all six families (Fig. 1) and was absent in 190 Arab-Muslim chromosomes of control subjects. Analysis of two SNP markers within the ABCA4 gene revealed a shared haplotype (rs472908-A and rs560426-G) in all affected patients who were homozygote for the c.4254-15del23 mutation.
|
|
| Discussion |
|---|
|
|
|---|
More than 500 ABCA4 mutations have been identified as causing different retinal diseases, allowing a proposed genotype-phenotype correlation model.4 5 17 The simplified model suggests that patients with two severe mutations have retinitis pigmentosa, patients with one severe and one moderate mutation have CRD, patients with one severe and one mild mutation have Stargardt disease, and patients with only one severe or moderate mutation are at increased risk for age-related macular degeneration. As can be expected, actual genotype-phenotype correlations are more complex, and deviations from this model have been reported.5 17 18 Interestingly, as in the homozygote patients described here, progression from an initially mild, characteristic phenotype to a severe one, usually CRD, may also occur over time.18 19 20
The major limitation in obtaining an accurate genotype-phenotype correlation model is the correct interpretation of the effect of a given mutation on protein structure or function. This is particularly difficult with potential splicing mutations, which can lead to mild or severe mutations. Analysis of such mutations is challenging because of technical difficulties in amplifying ABCA4 mRNA from readily available tissues, such as peripheral blood and lymphoblastoid cells.4 In only one study thus far15 has reliable splicing data been obtained through this system, leading to an unexpected result: a frequent base substitution (c.2588G>C) in the first base of exon 17, initially interpreted as a missense mutation (Gly863Ala), created a splicing defect, resulting in a deletion of one amino acid (Gly863). This result emphasizes the importance of accurate mRNA analysis for each suspected splicing mutation before any genotype-phenotype assumptions can be made. Our nested RT-PCR analysis of the retina and lymphoblastoid cells revealed an unexpected result. We found that ABCA4 produced four different transcripts in the normal retina through an alternative-splicing mechanism. The two most common transcripts are the wild-type ABCA4 mRNA and a variant (ABCA_v2) in which exons 28 and 29 are skipped. This deletion causes a frameshift and is therefore likely to be recognized and degraded by the nonsense mediated decay (NMD) mechanism.21 The other two transcripts (v3 and v4) have in-frame deletions and are expressed at very low levels, probably producing low amounts of nonfunctional ABCA4 proteins. The splicing region of all five ABCA4 transcripts described thus far (the wild-type transcript, a splicing variant with part of exon 30 as reported previously,3 4 and three additional splice variants reported here) is located between exons 28 and 30 of the ABCA4 gene. Interestingly, this region contains a number of cryptic splice sites4 and a few splice-site mutations. The novel splicing mutation we identified in this study, c.4254-15del23, prevents the production of the wild-type ABCA4 protein and is likely to be a null mutation. However, we cannot exclude the possibility that small amounts of the wild-type protein are still translated in the retinas of these patients. If such a low level of expression indeed exists, it may explain the delayed appearance of widespread retinal degeneration in our patients compared with other patients who manifest early, full-blown CRD or retinitis pigmentosa because of homozygosity for null ABCA4 mutations.
| Acknowledgements |
|---|
| Footnotes |
|---|
Supported by the American Health Assistance Foundation (M2004–003), the Israeli Science Foundation (Grant 484/04), the Chief Scientist at the Israeli Ministry of Health (Grant 5807), and the Yedidut Research Grant.
Submitted for publication February 26, 2007; revised April 25, 2007; accepted July 2, 2007.
Disclosure: A. Beit-Ya'acov, None; L. Meissonnier-Mizrahi, None; A. Obolensky, None; C. Landau, None; A. Blumenfeld, None; A. Rosenmann, None; E. Banin, None; D. Sharon, None
The publication costs of this article were defrayed in part by page charge payment. This article must therefore be marked "advertisement" in accordance with 18 U.S.C.
1734 solely to indicate this fact.
Corresponding author: Dror Sharon, Department of Ophthalmology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel; dror.sharon1{at}gmail.com.
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
A. V. Cideciyan, M. Swider, T. S. Aleman, Y. Tsybovsky, S. B. Schwartz, E. A.M. Windsor, A. J. Roman, A. Sumaroka, J. D. Steinberg, S. G. Jacobson, et al. ABCA4 disease progression and a proposed strategy for gene therapy Hum. Mol. Genet., March 1, 2009; 18(5): 931 - 941. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Bandah, S. Merin, M. Ashhab, E. Banin, and D. Sharon The Spectrum of Retinal Diseases Caused by NR2E3 Mutations in Israeli and Palestinian Patients Arch Ophthalmol, March 1, 2009; 127(3): 297 - 302. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |